欣安立适：一种新型带状疱疹疫苗。
Shingrix: A New Herpes Zoster Vaccine.
作者信息
Maltz Fraidy, Fidler Brooke
出版信息
P T. 2019 Jul;44(7):406-433.
Abstract
Shingrix, a new vaccine for herpes zoster.
摘要
欣安立适，一种新型带状疱疹疫苗。
相似文献
1
Shingrix: A New Herpes Zoster Vaccine.欣安立适：一种新型带状疱疹疫苗。
P T. 2019 Jul;44(7):406-433.
2
Recombinant Zoster Vaccine (Shingrix) to Prevent Herpes Zoster.重组带状疱疹疫苗（欣安立适）用于预防带状疱疹。
Nurs Womens Health. 2018 Oct;22(5):417-422. doi: 10.1016/j.nwh.2018.07.004. Epub 2018 Aug 24.
3
Shingrix for Herpes Zoster: A Review.用于带状疱疹的欣安立适：综述
Skin Therapy Lett. 2019 Jul;24(4):5-7.
4
Recombinant zoster vaccine (Shingrix): a new option for the prevention of herpes zoster and postherpetic neuralgia.重组带状疱疹疫苗（欣安立适）：预防带状疱疹及带状疱疹后神经痛的新选择。
Korean J Pain. 2020 Jul 1;33(3):201-207. doi: 10.3344/kjp.2020.33.3.201.
5
Shingrix: The New Adjuvanted Recombinant Herpes Zoster Vaccine.欣格来福：新型佐剂重组带状疱疹疫苗。
Ann Pharmacother. 2018 Jul;52(7):673-680. doi: 10.1177/1060028018758431. Epub 2018 Feb 18.
6
An ODE-based mixed modelling approach for B- and T-cell dynamics induced by Varicella-Zoster Virus vaccines in adults shows higher T-cell proliferation with Shingrix than with Varilrix.基于 ODE 的混合建模方法用于研究成人带状疱疹病毒疫苗诱导的 B 细胞和 T 细胞动力学，结果显示，与 Varilrix 相比，Shingrix 可引起更高的 T 细胞增殖。
Vaccine. 2019 May 1;37(19):2537-2553. doi: 10.1016/j.vaccine.2019.03.075. Epub 2019 Apr 8.
7
Which patients should receive the herpes zoster vaccine?哪些患者应该接种带状疱疹疫苗？
JAAPA. 2019 Sep;32(9):18-20. doi: 10.1097/01.JAA.0000578788.69674.2b.
8
Public Health Impact and Cost-Effectiveness of Non-live Adjuvanted Recombinant Zoster Vaccine in Canadian Adults.非活佐剂重组带状疱疹疫苗对加拿大成年人的公共卫生影响和成本效益。
Appl Health Econ Health Policy. 2019 Oct;17(5):723-732. doi: 10.1007/s40258-019-00491-6.
9
Avoiding rash decisions about zoster vaccination: insights from cost-effectiveness evidence.避免对带状疱疹疫苗接种做出草率决定：成本效益证据的见解。
BMC Med. 2018 Dec 18;16(1):238. doi: 10.1186/s12916-018-1231-3.
10
Herpes zoster subunit vaccine for the prevention of herpes zoster.用于预防带状疱疹的带状疱疹亚单位疫苗。
Am J Health Syst Pharm. 2018 Jun 15;75(12):861-869. doi: 10.2146/ajhp170399.
引用本文的文献
1
Clinical characteristics and treatment of varicella zoster virus central nervous system infection in an Australian tertiary hospital.澳大利亚一家三级医院水痘带状疱疹病毒中枢神经系统感染的临床特征与治疗
Intern Med J. 2025 Jul;55(7):1152-1160. doi: 10.1111/imj.70076. Epub 2025 Apr 21.
2
Vaccines in Dermatology-Present and Future: A Review.皮肤病学中的疫苗：现状与未来综述
Vaccines (Basel). 2025 Jan 26;13(2):125. doi: 10.3390/vaccines13020125.
3
An Exploratory Investigation of Representations of Herpes Zoster and Adjuvanted Recombinant Herpes Zoster Vaccination in a Sample of Fragile Adults in Italy.意大利脆弱成年人样本中带状疱疹及佐剂重组带状疱疹疫苗接种情况的探索性调查
Pathogens. 2025 Feb 4;14(2):145. doi: 10.3390/pathogens14020145.
4
Molecular dynamics simulation based prediction of T-cell epitopes for the production of effector molecules for liver cancer immunotherapy.基于分子动力学模拟预测肝癌免疫治疗效应分子的T细胞表位。
PLoS One. 2025 Jan 3;20(1):e0309049. doi: 10.1371/journal.pone.0309049. eCollection 2025.
5
The relationship between Zoster serology, vaccination uptake and infection rates: a single-centre cross-sectional study.带状疱疹血清学、疫苗接种率与感染率之间的关系：一项单中心横断面研究。
Rheumatol Adv Pract. 2024 Oct 8;8(4):rkae127. doi: 10.1093/rap/rkae127. eCollection 2024.
6
Lipo-pam™ adjuvanted herpes zoster vaccine induces potent gE-specific cellular and humoral immune responses.Lipo-pam™ 佐剂带状疱疹疫苗可诱导产生强效的gE特异性细胞免疫和体液免疫反应。
NPJ Vaccines. 2024 Aug 17;9(1):150. doi: 10.1038/s41541-024-00939-4.
7
Two cases of atypical herpes zoster in people taking oral Janus kinase inhibitors.两例服用口服Janus激酶抑制剂患者出现非典型带状疱疹。
CMAJ. 2024 Jul 14;196(25):E875-E877. doi: 10.1503/cmaj.240221.
8
Anti-Herpes Zoster Vaccination of Fragile Patients in Hospital Setting: A Nudge Intervention in Italy.医院环境中脆弱患者的抗带状疱疹疫苗接种：意大利的一项助推干预措施。
Vaccines (Basel). 2024 Apr 19;12(4):442. doi: 10.3390/vaccines12040442.
9
Protective RNA nanovaccines against subspecies .针对. 亚属的保护性 RNA 纳米疫苗
Front Immunol. 2023 Jun 8;14:1188754. doi: 10.3389/fimmu.2023.1188754. eCollection 2023.
10
Status of Herpes Zoster and Herpes Zoster Vaccines in 2023: A position paper.2023 年带状疱疹和带状疱疹疫苗的现状：立场文件。
Rev Esp Quimioter. 2023 Jun;36(3):223-235. doi: 10.37201/req/004.2023. Epub 2023 Feb 8.
本文引用的文献
1
Shingrix: The New Adjuvanted Recombinant Herpes Zoster Vaccine.欣格来福：新型佐剂重组带状疱疹疫苗。
Ann Pharmacother. 2018 Jul;52(7):673-680. doi: 10.1177/1060028018758431. Epub 2018 Feb 18.
2
Recommendations of the Advisory Committee on Immunization Practices for Use of Herpes Zoster Vaccines.免疫实践咨询委员会关于带状疱疹疫苗使用的建议。
MMWR Morb Mortal Wkly Rep. 2018 Jan 26;67(3):103-108. doi: 10.15585/mmwr.mm6703a5.
3
Immunogenicity and Safety of an Adjuvanted Herpes Zoster Subunit Vaccine Coadministered With Seasonal Influenza Vaccine in Adults Aged 50 Years or Older.50岁及以上成年人中，佐剂重组带状疱疹亚单位疫苗与季节性流感疫苗同时接种的免疫原性和安全性
J Infect Dis. 2017 Dec 12;216(11):1352-1361. doi: 10.1093/infdis/jix481.
4
Immunogenicity and Safety of the HZ/su Adjuvanted Herpes Zoster Subunit Vaccine in Adults Previously Vaccinated With a Live Attenuated Herpes Zoster Vaccine.在先前接种过减毒活带状疱疹疫苗的成年人中，重组带状疱疹亚单位疫苗（含 HZ/su 佐剂）的免疫原性和安全性
J Infect Dis. 2017 Dec 12;216(11):1343-1351. doi: 10.1093/infdis/jix482.
5
Modeling The Economic Burden Of Adult Vaccine-Preventable Diseases In The United States.美国成人疫苗可预防疾病的经济负担建模
Health Aff (Millwood). 2016 Nov 1;35(11):2124-2132. doi: 10.1377/hlthaff.2016.0462. Epub 2016 Oct 12.
6
Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older.带状疱疹亚单位疫苗在 70 岁及以上成人中的疗效。
N Engl J Med. 2016 Sep 15;375(11):1019-32. doi: 10.1056/NEJMoa1603800.
7
Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults.带状疱疹亚单位佐剂疫苗在老年人中的功效。
N Engl J Med. 2015 May 28;372(22):2087-96. doi: 10.1056/NEJMoa1501184. Epub 2015 Apr 28.
8
Clinical practice: Herpes zoster.临床实践：带状疱疹。
N Engl J Med. 2013 Jul 18;369(3):255-63. doi: 10.1056/NEJMcp1302674.
Zotero 插件